The incidence of malignant pleural mesothelioma (MPM) is rising in most parts of the world, as a consequence of widespread exposure to asbestos ([@bib14]; [@bib32]; [@bib34]; [@bib15]). Owing to the long latent period following exposure, MPM is often diagnosed late in life. An increasing proportion of elderly patients is reported by several epidemiological studies and mesothelioma registers in industrialised countries ([@bib24]; [@bib10]; [@bib33]; [@bib30]; [@bib29]; [@bib28]). However, there are no specific guidelines for their management. As a consequence, clinical uncertainty often results in suboptimal or excessively toxic treatments, which ultimately may lead to poorer outcomes as compared with younger patients ([@bib12]; [@bib13]). Although geriatric oncology has definitely been accepted as a defined field of clinical activity and research ([@bib27]; [@bib22]), elderly patients with relatively rare tumours such as MPM are under-represented in clinical trials. Median age of patients enrolled in the cisplatin/pemetrexed phase III trial, which has established the current standard of systemic therapy for MPM, was 61 years ([@bib41]). In that trial, the percentage of patients aged ⩾70 years was about 19% (Vogelzang and Symanowski, personal communication). Schedules with carboplatin have been implemented for MPM patients who are unfit to receive cisplatin; however, the proportion of elderly patients in these trials remained low, ranging from 21 to 34%, with median age of study populations of 65--67 years ([@bib5], [@bib7]; [@bib3]). Prospective as well as retrospective data regarding prognostic factors and the efficacy and tolerability of anticancer treatments in elderly patients affected by MPM are lacking. The aim of this study was to retrospectively evaluate the diagnostic and therapeutic management of a large series of elderly MPM patients referred to six Italian Centres in a 7-year span after the availability of pemetrexed, focusing on the factors affecting their survival, including comorbidity.

Patients and methods
====================

Patient selection
-----------------

The survey was conducted in six Italian Oncology Departments with high MPM accrual and expertise (Cliniche Humanitas Gavazzeni, Bergamo; Ospedale S. Spirito, Casale Monferrato; Ospedale SS Antonio e Biagio, Alessandria; Humanitas Cancer Center, Rozzano, Milan; Ospedale Villa Scassi, Sampierdarena, Genova; Istituto Oncologico Veneto, Padova). The clinical records of all elderly patients (⩾70 years old) with MPM diagnosed from January 2005 to November 2011 were reviewed. For each patient, age, asbestos exposure, gender, histology, stage, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), Charlson Comorbidity Index (CCI) ([@bib8]) and treatment modalities were analysed and correlated to overall survival (OS). Asbestos exposure was evaluated based on information reported in clinical records; exposure was classified as occupational, environmental, uncertain or not documented. Stage was evaluated according to the International Mesothelioma Interest Group (IMIG) staging system ([@bib35]). Best tumour response to therapy was assessed according to modified RECIST criteria for MPM ([@bib2]). Charlson Comorbidity Index was calculated by a Microsoft Excel Macro, available on the web with no restrictions and licence ([@bib20]). An informed consent was obtained by each patient before any diagnostic or therapeutic procedure. All patient data were made fully anonymous.

Statistical analyses
--------------------

The primary objective of this study was OS, which was calculated as the time from diagnosis until death from any cause; patients who were alive on the date of last follow-up were censored on that date. overall survival was analysed according to the following variables: gender, age (\<75 years *vs* ⩾75 years), ECOG-PS (0 *vs* ⩾1), histotype (epithelial *vs* non-epithelial), stage (I--II *vs* III--IV IMIG stage), asbestos exposure (yes *vs* no/uncertain), presence of comorbidities (CCI 0 *vs* ⩾1), and treatment with any pemetrexed-based regimen, including single-agent therapy (yes *vs* no). Actuarial survival curves were generated using the Kaplan--Meier method ([@bib25]). Median follow-up time was estimated with the use of the inverse Kaplan--Meier method ([@bib38]). All parameters were evaluated as categorical variables by univariate analysis using the log-rank test to compare groups. For age, the median value of the whole population (75 years) was chosen as cutoff for the analysis. Statistically significant variables were regressed using multivariate Cox proportional hazards model. The effect of each factor was expressed as hazard ratio (HR) with 95% confidence intervals (CIs), considering only statistically significant factors in the multivariable model. Statistical significance was set at *P*\<0.05 for each evaluation. All statistical analyses were performed with the R software package, version 2.0.1 (R Foundation for Statistical Computing, Institute for Statistics and Mathematics, Wien, Austria).

Results
=======

Demographics
------------

Out of a total of 715 consecutive MPM cases diagnosed at the six participating Hospitals in the study period, 241 elderly patients with complete clinical data were identified (34% of the whole population). The patient referral by Institution is reported in [Table 1](#tbl1){ref-type="table"}. Of note, the proportion of elderly individuals was similar in all centres. Patient characteristics are listed in [Table 2](#tbl2){ref-type="table"}. Median age was 75 years, with a range from 70 to 92. Forty-eight cases (20%) were 80 years or older. Patients were mainly males (64%), with ECOG-PS of 0--1 (94%). Asbestos exposure was documented in 80% of cases; a high rate of environmental exposure was reported, mainly owing to the contribution of two centres (Casale Monferrato and Alessandria, that are located in the same geographical area). Diagnosis of MPM was histological in the vast majority of subjects, with 5% only having a cytological or clinical-radiological definition alone. More than two thirds of patients had an epithelioid histological subtype. IMIG stage was I--II in 149 patients (62%), III--IV in 92 (38%). The details of comorbidity scores according to CCI are reported in [Table 3](#tbl3){ref-type="table"}. No major comorbidity (CCI=0) was found in 145 patients (60%), whereas at least one comorbid condition (CCI⩾1) was reported in 92 (38%). Main reported comorbidities were peripheral vascular disease, diabetes and chronic liver disease. In four cases, CCI was unknown.

Treatment
---------

Overall, 198 patients (82%) underwent an active treatment, whereas 43 (18%) received best supportive care (BSC) only. Active treatment consisted of multimodality therapy (including any kind of surgery, chemotherapy and in some cases radiotherapy) in 18 and chemotherapy as single modality therapy in 180 patients. In patients ⩾75 years (*n*=122), 3 cases were treated with multimodality therapy, 86 with chemotherapy, and 33 received BSC. The respective numbers for patients ⩾80 years (*n*=48) were 0, 30 and 18 cases.

Histological diagnosis in the 18 cases treated with multimodality therapy was first obtained at thoracoscopy; subtype in this subset was epithelioid in 15, mixed in 2, sarcomatoid in 1 case. Pleurodesis was done in nine patients. Pleurodesis alone was not considered a surgical procedure. Most patients (12 cases) underwent pleurectomy/decortication, six had extrapleural pneumonectomy. No perioperative mortality occurred. Patients were selected for surgery based on early stage (I--II), good performance status (ECOG-PS ⩽1), absence of relevant comorbidities (CCI ⩽1) and adequate cardiac and pulmonary function.

First-line chemotherapy (as single treatment or as a part of multimodality therapy) was mainly pemetrexed based, with most patients treated with the combination of pemetrexed and carboplatin ([Table 4](#tbl4){ref-type="table"}). Overall, 178 patients (74% of the study population) received a pemetrexed-based regimen. Response was not assessed or not reported in 23 cases; a complete or partial response was achieved in 1 and 45 patients, respectively, for a response rate of 23% 75 patients had stable disease (38%) and 54 progressed; therefore, overall disease control rate was 61%. A second-line treatment was administered to 87 patients (44% of patients treated with first-line chemotherapy, 36% of the whole study group). About a quarter of patients were re-challenged with pemetrexed; the remaining received a gemcitabine or vinorelbine-based regimen, or an experimental agent ([Table 4](#tbl4){ref-type="table"}). Overall, response to second-line therapy was observed in six cases (7%), with 26 patients having stable disease (30% overall disease control 37%). In pemetrexed-retreated patients, response rate was 20% (five cases); stable disease was registered in 11 patients (44% overall disease control 64%).

Survival analysis
-----------------

With a median follow-up of 40.1 months (range 0.2--80.8 months), 215 patients died and 26 are still alive. [Figure 1](#fig1){ref-type="fig"} shows the actuarial OS curve for the entire population; the median OS was 11.4 months. The 1-year and 2-year estimates were 48.4% (95% CI: 41.9--54.6%) and 21% (95% CI 16.0--26.5%), respectively. In the univariate model ([Table 5](#tbl5){ref-type="table"}), age ⩾75 years, documented asbestos exposure, non-epithelioid histology, advanced (III--IV) IMIG stage, presence of any comorbidity (CCI⩾1) and absence of a pemetrexed-based treatment were significantly correlated to a shorter OS. No survival difference was observed according to gender. Age remained a prognostic factor even when a cutoff of 80 years was considered, with patients⩾80 years showing a median OS of 6.7 months as compared with 13.1 months for patients\<80 years (*P*\<0.001). In the multivariate analysis, non-epithelioid histology (HR 2.32; 95% CI 1.66--3.23, *P*\<0.001), age ⩾75 years (HR 1.44; 95% CI 1.08--1.93, *P*=0.014), advanced IMIG stage (HR 1.47; 95% CI 1.09--1.98, *P*=0.011), and the presence of comorbidities according to CCI (HR 1.38; 95% CI 1.02--1.85, *P*=0.034) were confirmed as significantly correlated to a shorter OS. On the contrary, asbestos exposure was not significantly related to OS (HR 1.28; 95% CI 0.89--1.85, *P*=0.183).

In the same model, treatment with pemetrexed was associated with improved OS (HR 0.40; 95% CI 0.28--0.56, *P*\<0.001). The OS curves according to significant prognostic factors are shown in [Figure 2](#fig2){ref-type="fig"}.

Discussion
==========

The incidence of MPM in elderly patients is steadily increasing in Western and industrialised countries. In Italy, mean age at diagnosis, according to the National Mesothelioma Register ([@bib29]) is 69.2 years, with a median latency time of 46 years from first asbestos exposure. Patients older than 65 years represent 67.4% of the registered MPM population, with 26.1% of cases diagnosed between 75 and 84 years. Similar data are reported by other epidemiological studies and mesothelioma registers ([@bib24]; [@bib10]; [@bib33]). Despite these epidemiologic data, retrospective and prospective studies in the elderly population affected by MPM are lacking. We have previously reported the results of a combined analysis of two phase II trials of carboplatin and pemetrexed as first-line therapy in 178 MPM patients ([@bib6]): in that study, pooled data of the two trials were retrospectively analysed for comparison between age groups. Elderly patients were defined as those ⩾70 years. No significant difference was observed in disease-control rate, time to disease progression and survival between elderly patients and their younger counterparts. Toxicity was comparable, with a slightly higher rate of haematological toxicity, mainly cumulative anaemia, in older patients. However, that study had the obvious shortcomings of a *post hoc* analysis in a group of selected elderly patients (eligible for a combination chemotherapy within a clinical trial); moreover, patients ⩾75 years were poorly represented and data on comorbidities were not available.

In the present study we collected and analysed the clinical data of 241 elderly patients consecutively diagnosed in six centres in nearly a 7-year span after the availability of therapy with pemetrexed. The study population was a true elderly population, as shown by the median age of 75 years, and sufficiently comparable to MPM cases of the Italian National Mesothelioma Register ([@bib29]), even though we had a higher percentage of female patients (36% *vs* 28%) and epithelioid histology (69% *vs* 51%). More importantly, the rate of histological diagnosis in our series was very high (95%), whereas in the National Register the rate of confirmed mesothelioma diagnosis was much lower (66.8% in the age cohort between 75 and 84 years and 37.1% in patients of 85 years and older, respectively). Therefore, we cannot exclude a partial selection in the study population by the exclusion of a few cases with dismal prognosis not referred to our centres for diagnosis owing to very advanced age and/or poor ECOG-PS.

Stage was reported as early (I--II according to the IMIG classification) in the majority of our patients. Early stage had a positive prognostic value in multivariate analysis, even though this result should be considered with caution, because of the well-known limitation of IMIG staging system in non-surgical patients ([@bib36]).

Our analysis confirmed, in the elderly MPM population, the prognostic role of histological subtype, with non-epitheliod tumours carrying a worse prognosis ([@bib11]; [@bib39]; [@bib4]; [@bib37]). Age ⩾75 years was also significantly correlated to a shorter OS. In MPM, as in several other cancers, older age has been generally considered a negative prognostic factor ([@bib23]; [@bib17]; [@bib40]). Apart from age-related biological differences, this may also have been influenced by the lack of specific trials in the elderly population, favouring a nihilistic attitude to treatment ([@bib13]).

Most elderly patients included in our study had a good ECOG-PS (0--1 in 94% of cases). However, assessment of PS is insufficient to properly address older cancer patients\' issues. In recent years, comprehensive geriatric assessment including determination of functional and cognitive status as well as comorbid conditions has emerged as a major tool for evaluation and treatment planning in this setting ([@bib16]). In particular, several studies have shown a significant correlation of comorbidity with patient outcome ([@bib1]; [@bib9]). Different methods of scoring have been proposed, but to date no ideal index has been set as a standard tool ([@bib21])Charlson Comorbidity Index is among the most used and validated comorbidity scores in cancer patients ([@bib8]). It is comprised of a multi-item summative scale with a pre-defined list of weighted items; therefore, it is applicable even in a retrospective setting ([@bib20]). The European Organization for Research and Treatment of Cancer has included CCI in the minimum dataset for the assessment of global health status and functional status in older cancer patients ([@bib31]). In our series of elderly MPM patients, the presence of any comorbidity evaluated by CCI (i.e., a CCI score ⩾1) was significantly correlated to a shorter OS in multivariate analysis, with a 38% increase of the risk of death.

Treatment with pemetrexed was a strong positive predictive factor for OS. Patients who received any pemetrexed-based chemotherapy survived longer (13.2 *vs* 4.9 months, *P*\<0.001), with an HR of 0.40. Detailed toxicity data were not available for all patients because of the retrospective nature of the study, and were, therefore, not considered in our analysis. However, treatment with pemetrexed in elderly patients with MPM was generally feasible, confirming previous data in MPM and other cancers ([@bib6]; [@bib19]; [@bib18]; [@bib26]).

In conclusion, in our retrospective study on a large series of elderly MPM patients, non-epithelioid histology, age ⩾75 years, advanced IMIG stage and the presence of comorbidity according to CCI were significant prognostic factors. Although a retrospective non-randomized evaluation of a treatment-related factor should be considered with great caution, therapy with pemetrexed-based chemotherapy was strongly correlated to survival. Based on these data, an invariably nihilistic attitude in MPM elderly patients should be avoided. Prospective dedicated trials in patients selected according to prognostic factors including comorbidity scales are warranted.
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###### Patient accrual by Centre

  **Institution**                           **Total no. of patients**   **No. Elderly patients**    **% Elderly patients**
  ----------------------------------------- --------------------------- -------------------------- ------------------------
  Casale Monferrato/Alessandria Hospitals   343                         124                                  36%
  Humanitas Cancer Center, Rozzano, Milan   132                         43                                   33%
  Genova Sampierdarena Hospital             95                          31                                   33%
  Cliniche Humanitas Gavazzeni, Bergamo     75                          25                                   33%
  Istituto Oncologico Veneto, Padova        60                          18                                   30%
  Total                                     715                         241                                  34%

###### Patient characteristics (*N*=241)

  **Variable**                                        **No. of patients**     **% of patients**
  ------------------------------------------------ -------------------------- -------------------
  Age                                               Median 75 (range 70--92)   
  ⩾75 yrs                                                     122             50%
  ⩾80 yrs                                                      48             20%
  **Gender**                                                                  
  Male                                                        155             64%
  Female                                                       86             36%
  **Asbestos exposure**                                                       
  Occupational                                                101             42%
  Environmental                                                91             38%
  Uncertain                                                    19             8%
  No documented exposure                                       30             12%
  **ECOG performance status**                                                 
  0                                                           157             65%
  1                                                            69             29%
  2                                                            11             4%
  Unknown                                                      4              2%
  **Diagnosis**                                                               
  Histological                                                228             95%
  Cytological only                                             6              2%
  Clinical-radiological only                                   7              3%
  **Histology**                                                               
  Epithelioid                                                 165             69%
  Mixed                                                        27             11%
  Sarcomatoid                                                  28             11%
  Unspecified/unknown[a](#t2-fn2){ref-type="fn"}               21             9%
  **IMIG stage**                                                              
  Early (I--II)                                               149             62%
  Advanced (III--IV)                                           92             38%

Abbreviations: ECOG=Eastern Cooperative Oncology Group; IMIG=International Mesothelioma Interest Group.

Nine patients with histological diagnosis and unspecified subtype; five with cytology only; seven with clinical/radiological diagnosis only.

###### Charlson Comorbidity Index (*N*=241)

  **CCI score**   **No. of patients**     **% of patients**
  --------------- --------------------- ----------------------
  0               145                    CCI=0 (*n*=145), 60%
  1               7                      CCI⩾1 (*n*=92), 38%
  2               11                               
  3               2                                
  4               39                     CCI⩾4 (*n*=72), 30%
  5               22                               
  6               4                                
  7               1                                
  8               0                                
  9               5                                
  10              1                                
  Unknown         4                                

Abbreviations: CCI=Charlson Comorbidity Index.

###### Patient treatment

  **Treatment**                                                       **No. of patients**  **% of patients**
  ------------------------------------------------------------------ --------------------- -------------------
  All                                                                         241           
   Multimodality treatment (MMT)                                              18           7
   Chemotherapy (CT)                                                          180          75
   Best supportive care only (BSC)                                            43           18
  First-line chemotherapy                                                     198           
   Pemetrexed-based chemotherapy                                              178          90%
  * *Pemetrexed single agent                                                  31           16
  * *Pemetrexed+carboplatin                                                   119          60
  * *Pemetrexed+carboplatin+bevacizumab[a](#t4-fn1){ref-type="fn"}            18           9
  * *Pemetrexed+cisplatin                                                     10           5
  * *Other                                                                    20           10%
  Second-line chemotherapy                                                    87            
  * *Pemetrexed-based chemotherapy[b](#t4-fn2){ref-type="fn"}                 25           29
  * *Gemcitabine-based regimen[c](#t4-fn3){ref-type="fn"}                     19           22
  * *Vinorelbine                                                              22           25
  * *Experimental trial                                                       21           24

Treatment was delivered within an experimental trial ([@bib7]).

Including 22 pemetrexed re-challenge, 2 second-line pemetrexed and 1 patient re-challenged with raltitrexed.

Thirteen single agent, six combination therapy (two patients were treated with gemcitabine/vinorelbine).

###### Prognostic factors analysis (N=241)

  **Univariate analysis**                       
  -------------------------------------- ------ ---------
  All                                    11.4    
  **Gender**                                     
   Male                                  11.4   0.460
   Female                                10.9    
  **Age (years)**                                
   \<75                                  13.4   0.006
   ⩾75                                   8.9     
  **Asbestos exposure**                          
   Occupational/ environmental           10.4   0.009
   Uncertain/not documented              15.2    
  **ECOG performance status**                    
   0                                     11.3   0.843
   ⩾1                                    10.9    
  **IMIG stage**                                 
   Early (I--II)                         15.2   0.021
   Advanced (III--IV)                    9.7     
  **Charlson Comorbidity Index**                 
   0                                     13.1   0.057
   ⩾1                                    9.4     
  **Histology**                                  
   Epithelioid                           14.5   \<0.001
   Non epithelioid                       7.4     
  **Pemetrexed (yes** ***vs*** **no)**           
   Yes                                   13.2   \<0.001
   No                                    4.9     

  **Multivariate analysis**                        
  ---------------------------- ------------------- ---------
  Age                          1.39 (1.04; 1.86)   0.026
  Charlson Comorbidity Index   1.42 (1.06; 1.91)   0.019
  Histology                    2.40 (1.73; 3.34)   \<0.001
  Pemetrexed                   0.41 (0.29; 0.58)   \<0.001

Abbreviations: CI=confidence interval; ECOG=Eastern Cooperative Oncology Group; HR=hazard ratio; IMIG=International Mesothelioma Interest Group; OS=overall survival.
